gametocyte specific factor 1 likeGenealiases: C20orf65 · FAM112A · dJ1028D15.4
Q-omics provides the consensus-scored GTSF1L profile across patient tissues and cancer cell-line models. GTSF1L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GTSF1L is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, GTSF1L RNA expression shows 11,947 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where GTSF1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTSF1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTSF1L survival associations across molecular data types. GTSF1L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTSF1L RNA expression–survival associations across cancer types. High GTSF1L expression shows unfavorable associations in MESO and UCEC, but favorable associations in HNSC, CESC, SKCM and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GTSF1L RNA expression.
This table summarizes GTSF1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GTSF1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTSF1L shows higher tumor expression in KIRC, HNSC, LUAD, UCEC, BRCA and STAD. The KIRC box plot shows higher GTSF1L RNA expression in tumor versus normal tissue (log2 FC = +0.266, t-test p < 0.001).
This table shows molecular features associated with GTSF1L in patient tissues and cancer cell lines. In patient samples, GTSF1L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GTSF1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
